BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 32573845)

  • 1. Heterogeneity of cancer-associated fibroblasts: Opportunities for precision medicine.
    Kanzaki R; Pietras K
    Cancer Sci; 2020 Aug; 111(8):2708-2717. PubMed ID: 32573845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes.
    Dzobo K; Dandara C
    OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer.
    Li X; Sun Z; Peng G; Xiao Y; Guo J; Wu B; Li X; Zhou W; Li J; Li Z; Bai C; Zhao L; Han Q; Zhao RC; Wang X
    Theranostics; 2022; 12(2):620-638. PubMed ID: 34976204
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer associated-fibroblast-derived exosomes in cancer progression.
    Li C; Teixeira AF; Zhu HJ; Ten Dijke P
    Mol Cancer; 2021 Dec; 20(1):154. PubMed ID: 34852849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CAFs to overcome anticancer therapeutic resistance.
    Saw PE; Chen J; Song E
    Trends Cancer; 2022 Jul; 8(7):527-555. PubMed ID: 35331673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNAs Delivery for Cancer-associated Fibroblasts' Activation and Drug Resistance in Cancer Microenvironment.
    Anajafi S; Paryan M; Khoshnazar A; Soleimani M; Mohammadi-Yeganeh S
    Endocr Metab Immune Disord Drug Targets; 2024; 24(3):333-347. PubMed ID: 37612874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions.
    Jenkins BH; Buckingham JF; Hanley CJ; Thomas GJ
    Pharmacol Ther; 2022 Dec; 240():108231. PubMed ID: 35718294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search of definitions: Cancer-associated fibroblasts and their markers.
    Nurmik M; Ullmann P; Rodriguez F; Haan S; Letellier E
    Int J Cancer; 2020 Feb; 146(4):895-905. PubMed ID: 30734283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
    Dzobo K; Dandara C
    OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
    Liu W; Wang M; Wang M; Liu M
    Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A centralized communication network: Recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors.
    Leask A
    Semin Cell Dev Biol; 2020 May; 101():111-114. PubMed ID: 31708414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors.
    Chan JSK; Sng MK; Teo ZQ; Chong HC; Twang JS; Tan NS
    Oncogene; 2018 Jan; 37(2):160-173. PubMed ID: 28892046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy.
    Khan GJ; Sun L; Khan S; Yuan S; Nongyue H
    Curr Drug Targets; 2018; 19(13):1573-1588. PubMed ID: 29468965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.
    Fiori ME; Di Franco S; Villanova L; Bianca P; Stassi G; De Maria R
    Mol Cancer; 2019 Mar; 18(1):70. PubMed ID: 30927908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity and Biology of Cancer-Associated Fibroblasts.
    Biffi G; Tuveson DA
    Physiol Rev; 2021 Jan; 101(1):147-176. PubMed ID: 32466724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel module and hub genes of distinctive breast cancer associated fibroblasts identified by weighted gene co-expression network analysis.
    Xu Y; Zhang Z; Zhang L; Zhang C
    Breast Cancer; 2020 Sep; 27(5):1017-1028. PubMed ID: 32383139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
    Aboulkheyr Es H; Zhand S; Thiery JP; Warkiani ME
    Integr Biol (Camb); 2020 Jul; 12(7):188-197. PubMed ID: 32638026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.
    Cheteh EH; Augsten M; Rundqvist H; Bianchi J; Sarne V; Egevad L; Bykov VJ; Östman A; Wiman KG
    Cell Death Dis; 2017 Jun; 8(6):e2848. PubMed ID: 28569790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.